Literature DB >> 18683999

Varenicline treatment for smokers with schizophrenia: a case series.

A Eden Evins, Donald C Goff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18683999      PMCID： PMC4060790          DOI： 10.4088/jcp.v69n0620a

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  5 in total

1.  Varenicline-induced manic episode in a patient with bipolar disorder.

Authors:  Izchak Kohen; Neil Kremen
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

2.  Exacerbation of schizophrenia by varenicline.

Authors:  Robert Freedman
Journal:  Am J Psychiatry       Date:  2007-08       Impact factor: 18.112

3.  Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.

Authors:  Karla B Mihalak; F Ivy Carroll; Charles W Luetje
Journal:  Mol Pharmacol       Date:  2006-06-09       Impact factor: 4.436

4.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia.

Authors:  R Freedman; M Hall; L E Adler; S Leonard
Journal:  Biol Psychiatry       Date:  1995-07-01       Impact factor: 13.382

5.  A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.

Authors:  A Eden Evins; Corinne Cather; Melissa A Culhane; Alan Birnbaum; Jonathan Horowitz; Elaine Hsieh; Oliver Freudenreich; David C Henderson; David A Schoenfeld; Nancy A Rigotti; Donald C Goff
Journal:  J Clin Psychopharmacol       Date:  2007-08       Impact factor: 3.153
  5 in total
  19 in total

1.  Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.

Authors:  Serena Tonstad; Simon Davies; Martina Flammer; Cristina Russ; John Hughes
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

Review 2.  Varenicline for tobacco dependence: panacea or plight?

Authors:  Jill M Williams; Michael B Steinberg; Marc L Steinberg; Kunal K Gandhi; Rajiv Ulpe; Jonathan Foulds
Journal:  Expert Opin Pharmacother       Date:  2011-06-06       Impact factor: 3.889

3.  The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.

Authors:  Kristin M Wildeboer-Andrud; Karen E Stevens
Journal:  Pharmacol Biochem Behav       Date:  2011-07-07       Impact factor: 3.533

4.  Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.

Authors:  Joo-Cheol Shim; Do-Un Jung; Sung-Soo Jung; Young-Soo Seo; Deuk-Man Cho; Ji-Heon Lee; Sae-Woom Lee; Bo-Geum Kong; Je-Wook Kang; Min-Kyung Oh; Sang-Duk Kim; Robert P McMahon; Deanna L Kelly
Journal:  Neuropsychopharmacology       Date:  2011-11-02       Impact factor: 7.853

5.  Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study.

Authors:  Elaine Weiner; Alison Buchholz; Agnes Coffay; Fang Liu; Robert P McMahon; Robert W Buchanan; Deanna L Kelly
Journal:  Schizophr Res       Date:  2011-03-04       Impact factor: 4.939

Review 6.  A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities.

Authors:  Taryn G Moss; Andrea H Weinberger; Jennifer C Vessicchio; Vincenza Mancuso; Sandra J Cushing; Michael Pett; Kate Kitchen; Peter Selby; Tony P George
Journal:  Am J Addict       Date:  2010 Jul-Aug

7.  Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial.

Authors:  Gladys N Pachas; Corinne Cather; Sarah A Pratt; Bettina Hoeppner; Johanna Nino; Sara V Carlini; Eric D Achtyes; Harry Lando; Kim T Mueser; Nancy A Rigotti; Donald C Goff; A Eden Evins
Journal:  J Dual Diagn       Date:  2012-05-11

Review 8.  Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings.

Authors:  Sharon M Hall; Judith J Prochaska
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

9.  Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline.

Authors:  Jennifer B McClure; Gary E Swan; Lisa Jack; Sheryl L Catz; Susan M Zbikowski; Tim A McAfee; Mona Deprey; Julie Richards; Harold Javitz
Journal:  J Gen Intern Med       Date:  2009-02-24       Impact factor: 5.128

10.  Visual hallucinations associated with varenicline: a case report.

Authors:  B Mahendri Raidoo; Eric C Kutscher
Journal:  J Med Case Rep       Date:  2009-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.